Modulation of the autonomic control of the failing heart

  • H. M. Snow
Conference paper


The failing heart operates with an abnormal combination of heart rate, stroke volume, and enddiastolic volume. This mismatch becomes more evident during exercise of patients with heart failure, when an increase in cardiac output is achieved with higher heart rate, a lower stroke volume and a higher enddiastolic volume. Using the β 1-adrenoceptor partial agonist xamoterol which lacks β 2-adrenoceptor agonism the response of the heart to sympathetic stimulation can be modulated. At rest and low levels of exercise xamoterol provides an inotropic support of the heart, whereas it reduces inappropriate tachycardia at higher levels. Thereby, xamoterol tends to normalize the balance of the inotropic and chronotropic control of the failing heart, because cardiac output is increased with a more normal combination of heart rate, stroke volume, and filling pressure. The beneficial effects of xamoterol are discussed as being especially important for failing ischemic hearts, because the balance between energy supply and energy demand may be improved by xamoterol.


Stroke Volume Partial Agonist Atrial Receptor Autonomic Control Sympathetic Stimulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Astrand PO, Cuddy ET, Saltin B, Stenberg J (1964) Cardiac output during submaximal and maximal work. J Appl Physiol 19: 268–274PubMedGoogle Scholar
  2. 2.
    Bainbridge FA (1915) The influence of venous filling upon the rate of the heart. J Physiol 50: 6584Google Scholar
  3. 3.
    Barlow JJ, Main BG, Snow HM (1981) ß-Adrenoceptor stimulant properties of amidoalkylamino substituted 1-anyl-2-ethanols and 1-(aryloxy)-2-propanols. J Med Chem 24: 315–322PubMedCrossRefGoogle Scholar
  4. 4.
    Barnett DB, Maguire M (1986) Comparison of the effects of chronic infusion of xamoterol and isoprenaline on rat ventricular ß-adrenoceptors. Br J Pharmacol 87: 223 PGoogle Scholar
  5. 5.
    Blackwood R, Marlow HR (1988) Xamoterol in the management of patients with exertional breathlessness and fatigue due to cardiac disease. J Am Coll Cardiol 11: 143AGoogle Scholar
  6. 6.
    Bruce RA, Hossack KF, Kusumi F, Clarke L (1979) Acute effect of oral propranolol on hemodynamic response to upright exercise. Am J Cardiol 44: 132–140PubMedCrossRefGoogle Scholar
  7. 7.
    Carlsson E, Ablad B, Brandstrom A, Carlsson B (1972) Differential blockade of the chrono-tropic effects of various adrenergic stimuli in the cat heart. Life Sci 11: 953–958CrossRefGoogle Scholar
  8. 8.
    Cook N, Richardson A, Barnett DB (1984) Comparison of the ß1 selective affinity of Prenalterol and Corwin demonstrated by radioligand binding. Eur J Pharmacol 98: 407–412PubMedCrossRefGoogle Scholar
  9. 9.
    Detry JR, Decoster PM, Brasseur LA (1983) Haemodynamic effects of Corwin (ICI 118587) a new cardioselective ß-adrenoceptor partial agonist. Eur Heart J 4: 584–591PubMedGoogle Scholar
  10. 10.
    Detry JR, Decoster PM, Buy J, Rousseau MF, Brasseur LA (1984) Antianginal effects of Corwin: a new ß-adrenoceptor partial agonist. Am J Cardiol 53: 439–443PubMedCrossRefGoogle Scholar
  11. 11.
    Epstein SE, Robinson BF, Kahler RL, Braunwald E (1965) Effects of ß-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest 44: 1745–1753PubMedCrossRefGoogle Scholar
  12. 12.
    Finegan RE, Marlow AM, Harrisson DC (1972) Circulatory effect of practolol. Am J Cardiol 29: 315–322PubMedCrossRefGoogle Scholar
  13. 13.
    Furnival CM, Linden RJ, Snow JM (1971 a) The inotropic and chronotropic effects of catecholamines on the dog heart. J Physiol 214: 15–28Google Scholar
  14. 14.
    Furnival CM, Linden RJ, Snow HM (1971 b) Reflex effects on the heart of stimulating left atrial receptors. J Physiol 218: 447–463Google Scholar
  15. 15.
    German and Austrian Study Group (1988) Double-blind placebo-controlled comparison of Digoxin and Xamoterol in chronic heart failure. Lancet 1: 489–493Google Scholar
  16. 16.
    Hetherington M, Teo KK, Haennel RG, Rossall RE, Kappagoda CT (1987) Response to upright exercise after myocardial infarction. Cardiovascular Res 21: 399–406CrossRefGoogle Scholar
  17. 17.
    Higginbotham MB, Morris KG, Williams RS, McHale PA, Coleman RE, Cobb FR (1986) Regulation of stroke volume during submaximal and maximal upright exercise in normal man. Circ Res 56: 281–291CrossRefGoogle Scholar
  18. 18.
    Jennings G, Bobick A, Oddie C, Restall R (1984) Cardioselectivity, kinetics, hemodynamics and metabolic effects of xamoterol. Clin Pharmacol Ther 35: 594–602PubMedCrossRefGoogle Scholar
  19. 19.
    Levy MN, Zieske A (1969) Autonomic control of cardiac pacemaker activity and atrioventricular transmission. J Appl Physiol 27: 465–470PubMedGoogle Scholar
  20. 20.
    Linden RJ, Snow HM (1974) The inotropic state of the heart. In: Linden RJ (ed) Recent advances in physiology. Churchill Livingstone, EdinburghGoogle Scholar
  21. 21.
    Lofdahl C-G, Svedmyr N (1984) Effects of xamoterol (ICI 118587) in asthmatic patients. Br J Clin Pharmacol 18: 597–601PubMedCrossRefGoogle Scholar
  22. 22.
    McCaffrey PM, Riddell JG, Shanks RG (1986) The selectivity of the partial agonist activity of xamoterol in man measured by its effects in the presence of ICI 118551. Br J Pharmacol 89: 594 PGoogle Scholar
  23. 23.
    Molajo AO, Bennett DH, Marlow HF, Snow HM, Bastain W (1987) The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease. Br J Clin Pharmacol 24: 373–379PubMedCrossRefGoogle Scholar
  24. 24.
    Nuttall A, Snow HM (1982) The cardiovascular effects of ICI 118587: a ß1-adrenoceptor partial agonist. Br J Pharmacol 77: 381–388PubMedCrossRefGoogle Scholar
  25. 25.
    Ohyagi A, Sasayama S, Nakamura Y, Lee JD, Kihara Y, Kawai C (1984) Effect of ICI 118587 on left ventricular function during gradual treadmill exercise in conscious dogs. Am J Cardiol 54: 1108–1113PubMedCrossRefGoogle Scholar
  26. 26.
    Parker JO, West RO, Di Giorgi S (1968) Hemodynamic effect of propranolol in coronary heart disease. Am J Cardiol 21: 11–19PubMedCrossRefGoogle Scholar
  27. 27.
    Pouleur H, Rousseau MF, Hanet C, Marlow HF, Charier AA (1987) Left ventricular sensitivity to ß-adrenoceptor-stimulating drugs in patients with ischaemic heart disease and varying degrees of ventricular dysfunction. Cire Res 4 [Suppl 11: 91–95Google Scholar
  28. 28.
    Reybrouck T, Amery A, Billiet L (1977) Hemodynamic response to graded exercise after chronic ß-adrenergic blockade. J Appl Physiol 42: 133–138PubMedGoogle Scholar
  29. 29.
    Rousseau MF, Brasseur LA, Detry JM (1973) Haemodynamic and electrocardiographic effects of practolol during upright exercise in coronary heart disease. Cardiovascular Res 7: 306–312CrossRefGoogle Scholar
  30. 30.
    Sasayama S, Yokawa S, Akiyama M, Mikawa M, Sakai 0 (1986) Cardiovascular effects of ICI 118587 a new ß-adrenoceptor partial agonist in man. Jpn Circ J 50: 636–643Google Scholar
  31. 31.
    Sato H, Inooe M, Matsyama T, Ozaki H, Shimazu T, Takeda H, Ishida Y, Kamada T (1987) Hemodynamic effects of the ß1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation 75: 213–220PubMedCrossRefGoogle Scholar
  32. 32.
    Starling EH (1920) On the circulatory changes associated with exercise. J R Army M Corps 34: 258–272Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • H. M. Snow
    • 1
  1. 1.Bioscience IIICI PharmaceuticalsMacclesfieldCheshireUK

Personalised recommendations